COVID-19: Bangladesh’s 1st homegrown vaccine gets clearance for human trial
Bangladesh’s first homegrown Coronavirus (COVID-19) vaccine has obtained clearance for a human trial in phase I.
The Bangavax vaccine, developed by local pharmaceutical company Globe Biotech, received clearance from the Directorate General of Drug Administration under the Ministry of Health and Family Welfare after the relevant authorities reviewed all the documents on all the previous trials.
“We’ve got the approval for phase I clinical trial of Bangavax,” Mohammad Mohiuddin, a senior official at Globe Biotech said.
He said the trial will be conducted among 60 healthy volunteers at Bangabandhu Sheikh Mujib Medical University hospital in Dhaka.
In November 2021, Bangavax, a single-dose COVID-19 vaccine, got ethical clearance from the Bangladesh Medical Research Council for a human trial on up to 64 healthy adult participants.
Globe Biotech applied for approval for a human trial on Nov. 1 last year, saying its vaccine has yielded “good results” in trials on monkeys.